El síndrome de Pisa / Pisa syndrome

Después de referir la historia del sídrome de Pisa descrito primeramente por Ekbom et al. en el año 1972 como efecto colateral de los neurolépticos y ampliada en 1991 por Patel et al. que, también, lo encontraron en un paciente con demencia de Alzheimer sin tratamiento neuroléptico y que consiste en una alteración distónica con inclinación lateral del tronco, se presentan a modo de ilustración dos nuevos casos clínicos que posiblemente introducen nuevas preguntas acerca de la etiopatogénesis de este síndrome. A continuación se resumen los escasos datos acerca de posibles medidas terapéuticas y, finalmente, se discute el problema de la aparente psicogénesis de esta alteración extrapiramidal

Medical and legal implications of side effects from neuroleptic drugs. A round-table discussion.

The side effects that may occur during treatment of schizophrenia with neuroleptic drugs are fully examined. Included are autonomic, extrapyramidal, other CNS, endocrine and metabolic, allergic, and skin and eye side effects. The differences between the side effect profiles of various antipsychotic drugs are noted. The restrictions imposed by laws designed to protect the patients's rights are evaluated with regard to the side effects of neuroleptic drugs. The meaning of informed consent is delineated.

Role of manganese in dystonia.

In this chapter, we have attempted to demonstrate that chronic manganese intoxication, in both animals and man, is a better model of dystonia than of Parkinson's disease. It is proposed that many of the monoamine and endocrine changes in dystonia may be the result of disturbances in manganese metabolism. A search for such modifications in human dystonia victims is presently underway. Preliminary studies indicate that head and pubic hair manganese concentrations are elevated in dystonia patients.